Methods and compositions for genetically manipulating genes and cells
OwnerTzumin Lee, Jorge Garcia Marques +1inventors
InventorsTzumin Lee, Jorge Garcia Marques, Hui-Min Chen
Life of this patent
Estimating the term…
Abstract
This disclosure provides methods and compositions for genetically manipulating genes and cells.
Claims31
A nucleic acid switch cassette comprising a target nucleic acid sequence flanked by first and second direct repeat nucleic acid sequences.
A method, comprising
- engineering a nucleic acid switch cassette into at least one desired nucleic acid sequence, wherein the nucleic acid switch cassette comprises a target nucleic acid sequence flanked by first and second direct repeat nucleic acid sequences;
- exposing the at least one desired nucleic acid comprising the nucleic acid switch cassette to a CRISPR system, wherein the CRISPR system comprises at least one guide RNA (gRNA) and a nuclease enzyme, wherein a spacer sequence in the at least one gRNA is complementary to the target nucleic acid sequence in the nucleic acid switch cassette, wherein, under appropriate conditions, the nuclease enzyme cleaves the target nucleic acid sequence to which the spacer sequence in the at least one gRNA binds;
- exposing the cleaved target nucleic acid sequence to single strand annealing (SSA) polypeptides or nucleic acids encoding SSA polypeptides;
- and
- determining the on-off status of the nucleic acid switch cassette of the desired nucleic acid sequence based on a phenotype.
A method, comprising
- providing a protein-encoding nucleic acid sequence comprising a nucleic acid switch cassette, wherein the nucleic acid switch cassette comprises a target nucleic acid sequence flanked by first and second direct repeat nucleic acid sequences and disrupts the protein-encoding nucleic acid sequence such that a functional protein is not produced;
- contacting the disrupted protein-encoding nucleic acid sequence comprising the nucleic acid switch cassette to a CRISPR/Cas9 system, wherein the CRISPR/Cas9 system comprises at least one guide RNA (gRNA) and a Cas9 enzyme, wherein a spacer sequence in the at least one gRNA is complementary to the target nucleic acid sequence in the nucleic acid switch cassette, wherein, under appropriate conditions, the Cas9 enzyme cleaves the target nucleic acid sequence to which the spacer sequence in the at least one gRNA binds;
- and
- contacting the cleaved target nucleic acid sequence to single strand annealing (SSA) polypeptides or nucleic acids encoding SSA polypeptides;
- thereby causing excision of the nucleic acid switch cassette from the disrupted protein-encoding nucleic acid sequence and restoring production of a functional protein.
A method, comprising
- providing a protein-encoding nucleic acid sequence comprising a nucleic acid switch cassette, wherein the nucleic acid switch cassette comprises a target nucleic acid sequence flanked by first and second direct repeat nucleic acid sequences and does not disrupt the protein-encoding nucleic acid sequence such that a functional protein is produced;
- contacting the protein-encoding nucleic acid sequence comprising the nucleic acid switch cassette to a CRISPR/Cas9 system, wherein the CRISPR/Cas9 system comprises at least one guide RNA (gRNA) and a Cas9 enzyme, wherein a spacer sequence in the at least one gRNA is complementary to the target nucleic acid sequence in the nucleic acid switch cassette, wherein, under appropriate conditions, the Cas9 enzyme cleaves the target nucleic acid sequence to which the spacer sequence in the at least one gRNA binds;
- and
- contacting the cleaved target nucleic acid sequence to single strand annealing (SSA) polypeptides or nucleic acids encoding SSA polypeptides;
- thereby causing excision of the nucleic acid switch cassette from the protein-encoding nucleic acid sequence, which results in disruption of the protein-encoding nucleic acid sequence such that a functional protein is not produced.
A kit, comprising:
- at least one cloning vector with direct repeats and a MCS between the direct repeats;
- at least one gRNA construct designed to accommodate a target sequence within the spacer sequence;
- and/or
- at least one CRISPR construct comprising a MCS.
A kit, comprising:
- a cloning vector with at least one switch cassette upstream from a MCS;
- and
- a plurality of cloning vectors, each comprising a different gRNA, wherein at least one gRNA matches a target sequence.
A kit, comprising:
- a cloning vector with an ON switch cassette upstream from a MCS;
- a cloning vector with an OFF switch cassette upstream from a MCS;
- a cloning vector comprising a nucleic acid sequence encoding a Cas9 enzyme downstream from a MCS;
- and
- a cloning vector comprising a first gRNA in the cascade, downstream from a MCS.
A nucleic acid construct comprising, in the 5′ to 3′ direction, a first exon, a disruptor exon and a second exon, wherein the first exon and the second exon together encode a functional moiety, wherein the first splice acceptor sequence comprises a nucleic acid sequence that is complementary to a spacer sequence of a first guide RNA (gRNA).
A transgenic organism comprising:
- a first transgenic construct comprising, in the 5′ to 3′ direction, a promoter, at least one guide RNA (gRNA), and a first detectable polypeptide;
- wherein a germ line of the first transgenic organism comprises a CRISPR system nuclease.
Dependencies are inferred from the claim text.